Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s Saridon-A Among 28 Painkillers Banned To Those Under 15 In Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Amid rising claims that it isn't moving fast enough to counter public concern over the safety of OTC painkillers, Korea FDA has banned Bayer Korea's painkiller Saridon-A, Samjin Pharm's Geworin and 26 other products from being prescribed or sold over the counter to those under 15 years of age

You may also be interested in...



S. Korea Group Urges Harder Look At IPA-Containing Painkillers

South Korea should take greater steps to ensure the safety of painkillers with isopropylantipyrine, according to the Korean Society for Pharmacoepidemiology and Risk Management. The group said the the drugs caused at least six cases of side effects as far back as 2002, and it counted six more recent cases of side effects that should have highlighted the risks. The Korean Food and Drug Administration identified three more cases in early December. IPA-containing painkillers are made in South Korea by Chong Kun Dang, Samjin Pharm, Dong-A Pharmaceutical and Bayer Korea. Chief side effects are cardiovascular disorders, spasms and unconsciousness. (Click here for more

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC071002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel